NO20043919L - Fremgangsmate for fremstilling av HMG-COA reduktaseinhiberende mevalonsyrederivater - Google Patents

Fremgangsmate for fremstilling av HMG-COA reduktaseinhiberende mevalonsyrederivater

Info

Publication number
NO20043919L
NO20043919L NO20043919A NO20043919A NO20043919L NO 20043919 L NO20043919 L NO 20043919L NO 20043919 A NO20043919 A NO 20043919A NO 20043919 A NO20043919 A NO 20043919A NO 20043919 L NO20043919 L NO 20043919L
Authority
NO
Norway
Prior art keywords
hmg
preparation
acid derivatives
coa reductase
mevalonic acid
Prior art date
Application number
NO20043919A
Other languages
English (en)
Inventor
Gottfried Sedelmeier
Christian Mathes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20043919L publication Critical patent/NO20043919L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/535Organo-phosphoranes
    • C07F9/5352Phosphoranes containing the structure P=C-
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26Radicals substituted by halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0033Iridium compounds
    • C07F15/004Iridium compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046Ruthenium compounds
    • C07F15/0053Ruthenium compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0073Rhodium compounds
    • C07F15/008Rhodium compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02Iron compounds
    • C07F15/025Iron compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/04Nickel compounds
    • C07F15/045Nickel compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/06Cobalt compounds
    • C07F15/065Cobalt compounds without a metal-carbon linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20043919A 2002-02-21 2004-09-20 Fremgangsmate for fremstilling av HMG-COA reduktaseinhiberende mevalonsyrederivater NO20043919L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0204129.1A GB0204129D0 (en) 2002-02-21 2002-02-21 Process for the manufacture of organic compounds
PCT/EP2003/001738 WO2003070717A1 (en) 2002-02-21 2003-02-20 Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives

Publications (1)

Publication Number Publication Date
NO20043919L true NO20043919L (no) 2004-09-20

Family

ID=9931523

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043919A NO20043919L (no) 2002-02-21 2004-09-20 Fremgangsmate for fremstilling av HMG-COA reduktaseinhiberende mevalonsyrederivater

Country Status (18)

Country Link
US (3) US7208623B2 (no)
EP (1) EP1478640A1 (no)
JP (1) JP2005520818A (no)
KR (1) KR100978970B1 (no)
CN (1) CN1318412C (no)
AU (1) AU2003218994B2 (no)
BR (1) BR0307801A (no)
CA (1) CA2473075A1 (no)
EC (1) ECSP045234A (no)
GB (1) GB0204129D0 (no)
IL (1) IL163279A (no)
MX (1) MXPA04008110A (no)
NO (1) NO20043919L (no)
NZ (1) NZ534394A (no)
PL (1) PL370596A1 (no)
RU (1) RU2335500C2 (no)
WO (1) WO2003070717A1 (no)
ZA (1) ZA200405436B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
CN101219992B (zh) 2003-02-12 2011-08-31 日产化学工业株式会社 匹伐他汀钙的晶形
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
EP1634870A1 (en) * 2004-08-27 2006-03-15 Zhejiang Hisun Pharmaceutical Co. Ltd. Process and intermediates for the selective synthesis of Fluvastatin
WO2006035286A2 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof
WO2007017117A1 (en) * 2005-07-28 2007-02-15 Lek Pharmaceuticals D.D. Process for the synthesis of rosuvastatin calcium
ES2564250T3 (es) 2006-05-03 2016-03-21 Msn Laboratories Private Limited Nuevo proceso para estatinas y sus sales farmacéuticamente aceptables de las mismas
WO2008044243A2 (en) 2006-10-09 2008-04-17 Manne Satyanarayana Reddy Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
US8318933B2 (en) * 2006-10-31 2012-11-27 Aurobindo Pharma Ltd Process for preparing rosuvastatin calcium
US8212035B2 (en) * 2007-02-08 2012-07-03 Aurobindo Pharma Ltd. Process for preparation of rosuvastatin calcium field of the invention
KR20090033183A (ko) * 2007-04-18 2009-04-01 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴 중간체 및 로수바스타틴의 제조 방법
WO2009009152A1 (en) * 2007-07-12 2009-01-15 Teva Pharmaceutical Industries Ltd. Rosuvastatin intermediates and their preparation
KR101063146B1 (ko) * 2008-11-10 2011-09-07 미래파인켐 주식회사 피타바스타틴 중간체의 제조방법 및 이를 이용한 피타바스타틴 헤미 칼슘염의 제조방법
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
EP2526099B1 (en) 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
US8912333B2 (en) * 2010-11-12 2014-12-16 Hetero Research Foundation Polymorphs of pitavastatin calcium
FR2970178B1 (fr) 2011-01-07 2014-06-20 Liliane Therese Jacquot Promedicaments pour une delivrance specifique au niveau du foie et une meilleure tolerance
CN103058925B (zh) * 2011-11-02 2015-09-02 石药集团中奇制药技术(石家庄)有限公司 一种匹伐他汀钙的制备方法
TWI516520B (zh) 2014-10-31 2016-01-11 財團法人工業技術研究院 波長轉換聚合物、其製法及包含其之波長轉換裝置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851427A (en) * 1985-10-25 1989-07-25 Sandoz Pharm. Corp. Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ATE158579T1 (de) * 1992-07-02 1997-10-15 Hoechst Ag Verfahren zur herstellung von (3r,5s)6-hydroxy- 3,5-0-isopropyliden-3,5-dihydroxy-hexansäure- tert.-butylester
CA2164685C (en) * 1994-12-07 2005-03-08 Takeshi Ohkuma Method for producing an alcohol
EP1300381B1 (en) 1995-12-06 2006-03-08 Japan Science and Technology Agency Process for preparing optically active alcohols
JP3159661B2 (ja) * 1997-02-21 2001-04-23 科学技術振興事業団 光学活性アルコール類の製造方法
US6187961B1 (en) * 1997-11-06 2001-02-13 Roche Vitamins Inc. Process for the preparation of trans-(R,R)-actinol
JPH11322649A (ja) * 1998-03-16 1999-11-24 Mitsubishi Chemical Corp 光学活性アルコールの製造方法
JPH11335385A (ja) * 1998-05-20 1999-12-07 Takasago Internatl Corp 遷移金属錯体および該錯体を用いた光学活性アルコールの製造方法
JP2000212110A (ja) * 1999-01-27 2000-08-02 Mitsubishi Chemicals Corp 光学活性α―アルキルベンジルアルコ―ル類の製造方法
JP3630002B2 (ja) * 1999-03-03 2005-03-16 三菱化学株式会社 光学活性1,2−ジオール類の製造方法
JP2000327659A (ja) * 1999-03-15 2000-11-28 Mitsubishi Chemicals Corp 光学活性ピリジルアルコール類の製造方法
US6603015B2 (en) * 1999-03-29 2003-08-05 University Of Kansas Synthesis of epothilones
US6211412B1 (en) * 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
JP2001104795A (ja) * 1999-10-13 2001-04-17 Mitsubishi Chemicals Corp ルテニウム触媒組成物
JP3720235B2 (ja) * 2000-03-14 2005-11-24 高砂香料工業株式会社 光学活性ルテニウムホスフィン錯体の製造方法及び該錯体を用いた光学活性アルコールの製造方法
US6605723B2 (en) * 2000-03-22 2003-08-12 Hoffman-La Roche Inc. Process for the preparation of ethanesul fonyl-piperidine derivatives
EP1284964A1 (en) * 2000-05-26 2003-02-26 Ciba SC Holding AG Process for the preparation of indole derivatives and intermediates of the process
WO2002008169A1 (en) * 2000-07-24 2002-01-31 Chirotech Technology Limited Ruthenium complexes and their use in asymmetric hydrogenation
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds

Also Published As

Publication number Publication date
JP2005520818A (ja) 2005-07-14
NZ534394A (en) 2006-10-27
ZA200405436B (en) 2005-06-17
AU2003218994B2 (en) 2007-08-09
CN1636004A (zh) 2005-07-06
WO2003070717A1 (en) 2003-08-28
KR20040111360A (ko) 2004-12-31
CN1318412C (zh) 2007-05-30
RU2004128256A (ru) 2005-06-27
EP1478640A1 (en) 2004-11-24
US20050159480A1 (en) 2005-07-21
KR100978970B1 (ko) 2010-08-30
PL370596A1 (en) 2005-05-30
US20070155970A1 (en) 2007-07-05
ECSP045234A (es) 2004-09-28
BR0307801A (pt) 2004-12-21
AU2003218994A1 (en) 2003-09-09
GB0204129D0 (en) 2002-04-10
IL163279A (en) 2010-06-30
RU2335500C2 (ru) 2008-10-10
US20080312462A1 (en) 2008-12-18
MXPA04008110A (es) 2004-11-26
CA2473075A1 (en) 2003-08-23
US7208623B2 (en) 2007-04-24

Similar Documents

Publication Publication Date Title
NO20043919L (no) Fremgangsmate for fremstilling av HMG-COA reduktaseinhiberende mevalonsyrederivater
IL269976B (en) Intermediate compounds for the preparation of quinazolines as inhibitors of human popatidylinositol 3-kinase delta
HK1199254A1 (en) Process for the preparation of aurora kinase inhibitors
NO20070753L (no) Fremgangsmåte for fremstilling av dihydropteridinoner
NO20043158L (no) Substituerte kinazolinderivater som inhibitorer av aurorakinaser
NO20054880D0 (no) Azaspiroalkanderivater som inhibitorer av metallproeaser
NO20054143D0 (no) Pyrimidinderivater for forhindringen av HIV-infeksjon
IL183188A0 (en) Pyrrolidyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors
HUP0303624A3 (en) N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad and process for preparation of the compounds
HUP0500851A2 (en) Process for the preparation of rosuvastatin
NO20043586L (no) Fremgangsmate for fremstilling av organiske forbindelser
IL183591A0 (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
AU3368400A (en) Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammationassociated with pulmonary disease
WO2005105079A3 (en) Novel imidazoles
IL172018A0 (en) Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
EP1883619B8 (en) Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
SI2341054T1 (sl) Postopek za pripravo zaviralcev HMG-CoA reduktaz
AU2002303145A1 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2008010087A3 (en) Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
AU2003245880A1 (en) Process for the preparation of thioalkylamine derivatives
AU2002359034A1 (en) Process for the preparation of simvastatin
NO20044332L (no) Forbedret fremgangsmate for fremstilling av nevirapine
NO20052396D0 (no) Fremgangsmate for fremstilling av spirolactonforbindelser
AU2002337601A1 (en) Process for the preparation of simvastatin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application